Autologous rapamycin resistant Th1/Tc1 cell therapy (Rapa Therapeutics)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAutologous rapamycin resistant Th1/Tc1 cell therapy (Rapa Therapeutics)
Drug Alias NameAutologous rapamycin resistant Th1/Tc1 cellsRAPA-201 Autologous T cellsRAPA-201
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Th1/Tc1 cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursLaryngeal NeoplasmsHead and Neck Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRapa Therapeutics Llc
China Registration ClassN/A

Develop Information

Active CompaniesRapa Therapeutics Llc
Inactive CompaniesN/A
Active IndicationsSolid tumoursLaryngeal NeoplasmsHead and Neck Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A